Withdrawal From Substance Disorder

Resources for Patients and Caregivers

Physical and mental symptoms that occur after stopping or reducing intake of a drug.

The characteristics of withdrawal depend on what drug is being discontinued.

Symptoms may include anxiety, fatigue, sweating, vomiting, depression, seizures, and hallucinations.

Treatment includes supportive care as well as medications to address symptoms and prevent complications.

Cluster Number:
Wiki Number: 57-Withdrawal from Substance Disorder
Diagnosis:
US Patients:
World Patients:
Sex Ratio:
Age Onset:
Brain Area:
Symptoms:
Progression:
Causes:
Medications:
Therapies:

CLICK HERE FOR THE FULL WIKIPEDIA ARTICLE

Youtube Video:

Alcohol Withdrawal Syndrome and Delerium Tremens

Amazon or Library Book: Alcoholism and Addiction Recovery

Click the book to link or order from Amazon.

Support Group: samhsa.gov; 800-662-4357

(U. S. Government Helpline)

Resources for Physicians, Counselors and Researchers

4 CURRENT ARTICLES
FROM PUBMED

The world-wide medical research
reports chosen for each diagnosis

Clicking each title opens the
PubMed article’s summary-abstract.

Zur Diskussion / Up for Discussion. Gefährdet die Cannabislegalisierung Kinder und Jugendliche? / Does Cannabis Legalization Endanger Children and Adolescents?
by Rainer Thomasius on December 3, 2024
Does Cannabis Legalization Endanger Children and Adolescents? The Cannabis Act (CanG) came into force on April 1, 2024. It regulates the "controlled supply of cannabis to adults for recreational purposes". In the USA, legalization has contributed to a decrease in the risk perception of the health hazards of consumption and an increase in risky consumption patterns, including among adolescents. The use of cannabis-related emergency and addiction treatment has risen sharply. Similar developments...
Persistent symptoms, exacerbations and drug side effects despite treatment in myasthenia gravis
by David Reyes-Leiva on December 3, 2024
CONCLUSIONS: There is a group of MG patients that suffers from persistent symptoms and exacerbations (11%-20%) or MG crises, and drug AEs, which may increase disease burden and impact on the healthcare system.
Safety, pharmacokinetics and pharmacodynamics of multiple-dose noiiglutide (SHR20004), a novel GLP-1 receptor agonist, in Chinese obese subjects without diabetes mellitus
by Yang Zou on December 2, 2024
CONCLUSIONS: Daily administration of noiiglutide using a titration method was well tolerated by Chinese obese participants without DM and showed potential therapeutic effect for weight loss.
The Temporal Changes in Ankle Joint Pathology, Pain and Secondary Osteoporosis in Collagen-Induced Arthritis Rats
by Qi Liu on December 2, 2024
CONCLUSION: The results suggested that the pain and joint inflammation might not be synchronized, possibly related to post-inflammatory hyperalgesia. CIA model could be used for the study of pain, also relatively stable and suitable for the study of RA with secondary osteoporosis.